Is a $2,131,889,198.56 market cap justified, page-26

That report is incredibly confused in its discussion of competitors to ⁶⁸GA-PSMA11 (Illucix)

In their consideration of the comparison of ⁶⁸GA-PSMA11 to ¹⁸F-DCFPyL they conclude they are about the same in terms of diagnostic value but they then go on to cite a paper that compared ⁶⁸Ga-PSMA to ¹⁸F-Fluciclovine that reached the conclusion that ⁶⁸Ga-PSMA was superior.

The problem is that ¹⁸F-Fluciclovine is an older class of tracer nothing like ¹⁸F-DCFPyL and is no way a serious competitor to Illucix. To make the report harder to read they don't refer to ¹⁸F-Fluciclovine by name instead they just call it 18F PET CT which is a fairly meaningless term which could confusingly also include ¹⁸F-DCFPyL.

I can't decide if they were simply out of their depth or were deliberately trying to downplay competition.